Rallybio Co. (NASDAQ:RLYB – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $10.00.
RLYB has been the topic of a number of recent research reports. Evercore ISI restated an “outperform” rating and issued a $15.00 price objective on shares of Rallybio in a research note on Monday, August 26th. HC Wainwright reiterated a “buy” rating and set a $6.00 price target on shares of Rallybio in a research note on Tuesday, September 3rd.
Institutional Trading of Rallybio
Rallybio Price Performance
Shares of RLYB opened at $1.10 on Thursday. Rallybio has a 1-year low of $1.08 and a 1-year high of $5.00. The stock has a market cap of $45.59 million, a PE ratio of -0.59 and a beta of -1.71. The firm has a fifty day moving average price of $1.19 and a 200 day moving average price of $1.49.
Rallybio (NASDAQ:RLYB – Get Free Report) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. The company had revenue of $0.30 million during the quarter. As a group, equities analysts expect that Rallybio will post -1.45 EPS for the current fiscal year.
About Rallybio
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Featured Stories
- Five stocks we like better than Rallybio
- The 3 Best Blue-Chip Stocks to Buy Now
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- How to Calculate Options Profits
- MarketBeat Week in Review – 9/16 – 9/20
- Find and Profitably Trade Stocks at 52-Week Lows
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.